NKG2A, a New Kid on the Immune Checkpoint Block

descriptionPublicationkeyboard_double_arrow_right Article 01 Dec 2018 English Publisher:Elsevier BVJournal:Cell, volume 175, pages 1,720-1,722 (issn: 0092-8674,

Copyright policy )

Authors: John B, Haanen; Vincenzo, Cerundolo;

doi: 10.1016/j.cell.2018.11.048

pmid: 30550781

NKG2A, a New Kid on the Immune Checkpoint Block

- Summary
- Subjects
- Metrics

Abstract

One of the major breakthroughs of cancer immunotherapy has come from blocking immune checkpoint molecules on tumor-reactive T cells. Now, two studies examine targeting of a novel immune checkpoint, NKG2A, that can be expressed on both NK cells and on CD8+ T cells, either combined with a tumor-targeting antibody or with a tumor-specific vaccine.

Related Organizations

University of Oxford
United Kingdom
Medical Research Council
United Kingdom
Netherlands Heart Institute
Netherlands
Antoni van Leeuwenhoek Hospital
Netherlands
MRC Human Immunology Unit
United Kingdom

Keywords

Killer Cells, Natural, Neoplasms, Humans, Immunotherapy, CD8-Positive T-Lymphocytes, Cancer Vaccines

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	93
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 1%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 1%